Lorviqua

lorlatinib · Pfizer Europe MA EEIG
AUTHORISED IN THE EU

What Lorviqua is used for

Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Lorviqua
Active substance
lorlatinib
Disease area
Carcinoma, Non-Small-Cell Lung
Medicine group
Antineoplastic agents;Protein kinase inhibitors
ATC code
L01ED05
Marketing authorisation holder
Pfizer Europe MA EEIG
Authorised in the EU since
2019

Official information

In the USA

Same active substance: Lorbrena

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Lorviqua used for?

Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.

What is the active substance in Lorviqua?

Lorviqua contains lorlatinib.

Who makes Lorviqua?

The EU marketing authorisation holder is Pfizer Europe MA EEIG.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.